938 Shares in Cencora, Inc. (NYSE:COR) Purchased by Simon Quick Advisors LLC

Simon Quick Advisors LLC bought a new position in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 938 shares of the company’s stock, valued at approximately $211,000.

Other institutional investors have also bought and sold shares of the company. Crossmark Global Holdings Inc. lifted its position in Cencora by 6.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 39,462 shares of the company’s stock worth $8,866,000 after buying an additional 2,351 shares in the last quarter. Ballentine Partners LLC raised its holdings in shares of Cencora by 4.1% during the 4th quarter. Ballentine Partners LLC now owns 8,880 shares of the company’s stock worth $1,995,000 after acquiring an additional 352 shares during the period. UMB Bank n.a. grew its holdings in shares of Cencora by 10.6% in the fourth quarter. UMB Bank n.a. now owns 1,248 shares of the company’s stock valued at $280,000 after purchasing an additional 120 shares during the period. Client 1ST Advisory Group LLC acquired a new stake in Cencora during the fourth quarter worth about $551,000. Finally, J2 Capital Management Inc purchased a new position in Cencora during the fourth quarter worth about $639,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. UBS Group boosted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company lowered their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $277.00.

Cencora Price Performance

Shares of COR opened at $248.45 on Friday. The company has a market cap of $48.02 billion, a P/E ratio of 33.08, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm’s 50 day moving average price is $237.51 and its 200 day moving average price is $234.66.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,187 shares of company stock worth $17,790,912. Company insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.